|
WO2021067930A1
|
|
Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics
|
|
WO2021067825A1
|
|
Oligonucleotides with nucleoside analogs
|
|
WO2021061437A1
|
|
CO-DELIVERY OF TGF-β SIRNA AND PDL1 SIRNA TO TREAT CANCER
|
|
WO2020139897A1
|
|
Silencing tgf-beta 1 and cox2 using sirnas delivered in combination with immune checkpoint inhibitors to treat cancer
|
|
WO2020139788A2
|
|
Targeted delivery of therapeutic molecules
|
|
CA3110300A1
|
|
Products and compositions
|
|
CA3101446A1
|
|
Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics
|
|
WO2018081726A2
|
|
Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
|
|
US2019030187A1
|
|
sirna/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral Infection
|
|
WO2014011512A1
|
|
Compositions and methods for "resistance-proof" sirna therapeutics for influenza
|
|
WO2012016139A2
|
|
Sirna compositions and methods for treatment of hpv and other infections
|
|
WO2011140285A2
|
|
Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application
|
|
CN102782573A
|
|
Rare earth-doped up-conversion nanoparticles for therapeutic and diagnostic applications
|
|
WO2010078517A2
|
|
Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
|
|
EP2217062A1
|
|
Multi-targeted rnai therapeutics for scarless wound healing of skin
|
|
WO2008154482A2
|
|
Sirna compositions and methods of use in treatment of ocular diseases
|
